New York, NY (PRWEB) October 14, 2013
Byetta lawsuits (http://www.byettalawsuit2013.com/) alleging that use of the Type 2 diabetes drug caused patients to develop pancreatic cancer are moving forward in a multidistrict litigation now underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to court records, plaintiffs’ attorneys filed a Joint Status Report on October 7th in preparation for the proceeding’s Initial Conference on October 17th. According to the document, plaintiffs have reached an agreement on a proposed leadership structure for the litigation. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
“Our Firm continues to be contacted by Byetta patients who may have developed pancreatic cancer while using this medication. We are pleased to see the Byetta pancreatic cancer litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm’s Byetta lawyers are currently offering free case evaluations to patients who took this drug and were diagnosed with pancreatic cancer, thyroid cancer or pancreatitis.
Byetta Pancreatic Cancer Litigation
Court records indicate that some 60 lawsuits involving incretin mimetic drugs, including Byetta, have been filed thus far in the proceeding underway in the Southern District of California. More than 40 of those lawsuits involve allegations over Byetta and pancreatic cancer.
According to the U.S. Food & Drug Administration (FDA), Byetta was brought to market in 2005, and was the first of the incretin mimetics class of Type 2 diabetes drugs. In 2008, the FDA issued a public warning about Byetta after receiving a high number of reports involving pancreatitis in patients who took the drug.* In February 2011, study published in the medical journal, Gastroenterology, suggested that patients taking Byetta faced a 3-fold increased risk of developing pancreatic cancer, as well as a 6-fold increased risk of pancreatitis. The same study also reported 30 cases of thyroid cancer among Byetta patients.**
This past March, the FDA announced it was investigating findings from an unpublished study that indicated drugs like Byetta could cause precancerous changes in the cells of the pancreas. A month later, the Institute for Safe Medicine Practices revealed that the FDA’s Adverse Event Reporting Database had received 263 reports of pancreatitis, 71 cases of pancreatic cancer, and 14 incidents of thyroid cancer among patients taking Byetta in a single 12-month period.
Byetta users who have been diagnosed with pancreatic cancer, pancreatitis, or thyroid cancer may be entitled to file a Byetta lawsuit. Click Here to learn how to contact a Byetta lawyer at Bernstein Leibhard LLP today. To schedule a free case review, please call 800-511-5092.
*fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm, FDA, August 18, 2008
**gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
***ismp.org/quarterwatch/pdfs/2012Q3.pdf, ISMP, April 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com